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Metyrapone with a ketone group is well known as inhibitor of 11β-hydroxylase which is the enzyme 
involved in the biosynthesis of cortisol. This drug is used clinically as a therapeutic drug for the treatment 
of Cushing’s syndrome. Although the clinical route is an oral administration, the plasma pharmacokinetics 
has not been reported in experimental animals and has not been evaluated in humans in details. In addition, 
there are few reports related to MP metabolism in both experimental animals and humans. Furthermore, the 
determination method of MP and its metabolites has not been completely established. In this study, after 
the method to simultaneously determine MP and its metabolites was developed, the pharmacokinetics was 
evaluated in in vitro and in vivo studies. 
 
1) Development of simultaneous determination of MP and its metabolites 
High-performance liquid chromatography ultra violet detection (HPLC-UV) method was developed to 
simultaneously determine MP and its five metabolites. The total run time was 65 min including HPLC 
column washing. No interfering peaks were obtained for plasma, urine and microsomal (Ms), cytosolic 
(Cyt) and mitochondrial (Mit) fractions in all the tested tissues. The calibration curves were constructed by 
plotting the peak-height ratio of MP and its metabolites to the IS in the range of 1.13 - 90.0 ng/mL, which 
all the correlation coefficient were 0.999. The lower limit of quantification (LLOQ) defined as the lowest 
concentration on the calibration curve, which the high sensitive analysis was developed by HPLC-UV. 
 
2) Pharmacokinetics after a single oral administration of MP to male Wistar rats 
When MP was orally administered at a dose of 50 mg/kg to male Wistar rats, MP was rapidly absorbed 
followed by rapid decline. By the rapid elimination, metyrapol (MPOL), metyrapone N-oxide II (MP NOII) 
and metyrapol N-oxide II (MPOL NOII) were immediately detected in plasma. On the other hand, only a 
 very small amount of MP was excreted in the urine. Taking into account these results, the rapid elimination 
of MP from plasma was more likely due to the rapid production of the above MP metabolites. Four 
metabolites (MPOL NOII>MP NOII>MPOL NOI>MPOL) were excreted in urine, which were different 
from the kinds and the rates of metabolites reported in male Sprague-Dawley (SD) rats. When the 
metabolic pathway of MP was predicted based on the amount of the metabolites observed in plasma and 
urine, it was presumed that MPOL NOII and MPOL NOI were produced from MPOL but not MP NOII and 
MP NOI. 
 
3) In vitro metabolism of MP in the subcellular fractions of tissues in male Wistar rats 
MP reductive and oxidative enzyme activities were investigated in the three subcellular fractions to 
clarify the primary tissue responsible for production of MP metabolites. Regarding the reductive enzyme 
activity to MPOL, it was suggested that the major metabolic tissue was the liver, judging from tissue 
weights. In addition, the activity was also highly observed in Ms and Mit of testis. On the other hand, the 
reductive and/or oxidative activities to other MP metabolites were too low in all the tissues to evaluate the 
major metabolic tissues. When sex difference in MP reductive activity in the liver Ms of rats was 
investigated, the difference was significantly observed from puberty. On the other hand, the developmental 
pattern of the activities from birth to adult age was different from that of the reductive activities of 
acetohexamide (AH) with a ketone group in previous report. In addition, MP reductive enzyme partially 
purified from the liver Ms of male Wistar rats did not metabolize AH, indicating that reductive enzyme of 
MP was different from that of AH. Higher MP reductive activity in males than in females is likely to the 
dependent on testosterone. Sex difference was also observed in the liver or kidney Ms and Cyt of five 
animals including rats. 
 
4) Inhibition of MP metabolism in the subcellular fractions of tissues 
The major enzyme involved in MP reductive and oxidative metabolism was investigated using the 
specific inhibitors of enzyme. It was suggested that 11β-hydroxysteroid dehydrogenase (11β-HSD) 1 
 mainly involved in the reductive metabolism to MPOL in Ms and Mit in the liver of male Wistar rats, and 
that cytochrome P450 (CYP) mainly involved in the oxidative metabolism to MP NOII. When the 
inhibition conctant (IC50) of the reductive activity for 11β-HSD1 inhibition was calculated in the Ms and 
Mit, glycyrrthetinic acid (GA), a selective 11β-HSD1 inhibitor, inhibited the activity in a dose-dependent 
manner with an IC50 value of 0.62 and 0.10 μM, respectively. In addition, in testis with the secondary 
higher MP reductive activity, the acitivies in the Ms and Mit were inhibited by GA in a dose-dependent 
manner with an IC50 value of 0.13 and 0.07 μM, respectively. The effect of 11β-HSD1 inhibition by the 
co-administration of GA on the pharmacokinetics of MP and its metabolites was investigated in an in vivo 
study. By the co-administration of GA, MPOL and MPOL NOII plasma concentrations decreased contrary 
to the increase in MP and MP NOII plasma concentrations. MP reductive and oxidative enzyme activites 
were also evaluated in the liver Ms, Cyt and Mit of humans. Similar to the results of male Wistar rats, the 
reductive metabolic activity to MPOL and the oxidative activity to MP NOII were the highest in the Ms. 
Taking into account these metabolic activities and the proposed MP metabolic pathway in male Wistar 
rats,it was guessed that the production pathways of three metabolites (MPOL, MPOL NOII and MP NOII) 
in humans were similar to the rats. From the viewpoint of inhibitor sensitivities, it was suggested that the 
major enzyme involved in MP reductive (MPOL) and oxidative (MP NOII) metabolism were 11β-HSD1 
and CYP, respectively, similar to male Wisrat ras. 
 
In conclusion, the present study elucidated the plasma pharmacokinetics and metabolites of MP in male 
Wistar rats after an oral administration. In addition, the study suggested that the major enzymes involved in 
MP reductive and oxidative metabolism were 11β-HSD1 and CYP, respectively, in both male Wistar ras 
and humans. The metabolism of MP in humans would be similar its in male Wistar rats, judging from the 
metabolic activities of MP to the three metabolites (MPOL, MPOL NOII and MP NOII) and the proposed 
MP metabolic pathway in the rats. Therefore, male Wistar rats could be a relevant species for use in 
predicting drug-drug interactions of MP in humans. 
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       MP : X1 and X2; nothing 
       MP NOI : X1 ; nothing, X2; O 
       MP NOII : X1 ; O, X2; nothing 
       MPOL : X1 and X2; nothing 
       MPOL NOI : X1 ; nothing, X2; O 
       MPOL NOII : X1 ; O, X2; nothing 
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Fig. 2. Representative chromatograms of (A) MP and its five metabolites (MPOL NOI, 
MP NOI, MPOL NOII, MP NOII, MPOL) and an internal standard (IS), and (B) extract 
of control male rat liver microsomes. 
1: MPOL NOI, 2: MP NOI, 3: MPOL NOII, 4: MP NOII, 5: MPOL, 6: MP, 7: IS 
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Fig. 3. Calibration curves of MP and its five metabolites.  
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????????????? Fig. 4?????????????? Table 1?????
??MP ??????????????????????????????????
??????????????????????? 50 mg/kg??? 11-14?????MP
????? 0.25???? tmax?????????Table 1??MP??????????
??????????MP ? 0.61 ??? t1/2???????????????Fig. 4?
Table 1??MP????????MPOL???MP NOII????????? 2.0???
????? tmax??????????? 6??? 8???? tmax?????????
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Fig. 4. Plasma concentration profiles of MP and its metabolites after a single oral 
administration of MP at a dose of 50 mg/kg to male rats. 
Each data point represents the mean of three separate determinations and error bars represent 




Table 1. Pharmacokinetic parameters of MP and its metabolites after a single oral 











MP 0.25 255.5 0.99 216.0 219.6 
MPOL 2.0 156.5 0.66 833.9 835.8 
MPOL NOII 6.0 33.3 1.05 228.9 230.1 
MP NOII 2.0 21.4 6.13 192.0 245.1 
Each data point represents the mean of three separate determinations. The mean 
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? 3?? MP????????MP????????????? 
 
Wistar?????MP? 50 mg/kg??????????? 24?48??? 72??







?????? 0.12%??? LLOQ???? 
 
Fig. 5. Ratio of MP and its metabolites in urine at 24 h after a single oral administration 
of MP at a dose of 50 mg/kg to male rats. 
Each data point represents the mean of three separate determinations, and error bars represent 
standard deviation, n=3. Data represent the percentage of the total peak ratio of MP and its 
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Ms??????????Mit??????????Cyt?????????????
?????Fig. 7A????? Fig. 7A??????????????????MPOL?
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MP ???????????????MP ????????????????MP 
NOII??????????MPOL???????????????Fig. 7B??MP NOI
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protein????????????????? Cyt????????????????
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?????????Fig. 7B????????MP???????MPOL???????
?????MP NOII???MP NOI????????????????MPOL NOII
??????????????????????????????????0.01?0.26 
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??????????????????????????????????????
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??????????Fig. 7?????MPOL NOI????????????????
???????????????????????data not shown??  
 








Fig. 7. Activity for the reduction and oxidation of MP in mitochondrial (Mit), cytosolic 
(Cyt) and microsomal fractions (Ms) in male rat tissues. 
Each data point represents the mean of three separate determinations, and error bars represent 
standard deviation except for small intestine, subcutaneous fat and visceral fat, n = 3. Each 
data point represents the average of triple determinations, and error bars represent standard 
deviation regarding small intestine, subcutaneous fat and visceral fat, n=3. *: P < 0.05; 
statistical analysis was performed by Kruskal–Wallis and Dunn’s test. (A) MPOL, (B) MP 
NOII, (C) MP NOI, (D) MPOL NOII. 
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Fig. 8. Developmental profiles of MP reductase activities in liver microsomal fractions of 
male and female rats. 
Each data point represents the mean of six to eight separate determinations and error bars 
represent standard deviation.?; male, ?; female, Significantly different from male rats at 
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Fig. 9. Efect of castration of MP reductase activities in the liver microsomal fractions of 
male rats. 
Each data point represents the mean of three to six separate determinations and error bars 
represent standard deviation. Significantly different from control male rats (**; p<0.01, 
student’s t test) 
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Fig. 10. Sex-related differences of metyrapone reductase activities in (A) microsomal 
and (B) cytosolic frations from the liver of the rat, mouse, hamster guinea pig, and 
rabbit. 
Each data point represents the mean of three separate determinations, and error bars represent 
standard deviation, n = 3. ?; male, ?; female, Significantly different from male animals (*; 
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Fig. 11. Sex-related differences of metyrapone reductase activities in (A) microsomal and 
(B) cytosolic frations from the kidney of the rat, mouse, hamster guinea pig and rabbit. 
Each data point represents the mean of three separate determinations, and error bars represent 
standard deviation, n = 3. ?; male, ?; female, Significantly different from male animals (*; 
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Table 2. Substrate specificity of partially purified MP reductase for aldehyde and ketone 
compounds 
Substarate Relative activity (%) 
1 mM 4-benzoylpyridine 440 
1 mM Pyridine-4-aldehyde 229 
1 mM Pyridine-3-aldehyde 157 
1 mM 4-acetylpyridine 34 
1 mM p-nitroacetophenone 101 
1 mM Acetophenone 0 
1 mM Benzophenone 0 
10 mM DL-glyceraldehyde 0 
10 mM D-xylose 0 
10 mM D-Glucuronic acid 0 
1 mM Menadione 250 
1 mM MP 100 
1 mM Daunorubicin 0 
1 mM Ketoprofen 0 
1 mM Bufunolol 0 
1 mM Haloperidol 0 
1 mM Levobunolol 0 
1 mM AH 0 
1 mM fenbufen 0 
MP : Metyrapone, AH : Acetohexamide 
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? 5?? MP? in vitro??? in vivo?????????????? 
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? Ms ??? Mit ???? MPOL ??????????????? 1 μM T0504
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??????????? 62??? 68%????? 100 μM ketoconazole?CYP????
????????? 45??? 53%???????????????? Cyt ????
MP???????????????????????????100 μM quercetin??
??????????????????? 65%??????MP NOII???????
????100 μM ketoconazole??? 100 μM quercetin????? CYP???????
?????? 55 ??? 50%?????????????????????????
???????????MPOL ?????????? MP NOII ?????????
???????????????? 11β-HSD1??? CYP???????????? 
 
 
Table 3. Effects of various inhibitors on the production activity of MPOL and MP NOII 
in rat liver microsomal, mitochondrial and adrenal cytosolic fractions 
Measured substance  MPOL  MP NOII 
Subcellular fraction LMs LMit Acyt  LMs 
1 μM T0504  91.2±0.7 91.5±3.3 ?  ? 
1 μM GA  77.0±10.8 92.3±0.5 NT  ? 
100 μM Phenobarbital  19.4±6.1 20.5±7.2 ?  4.5±1.2 
1 mM Phenobarbital  61.5±4.2 68.4±6.7 ?  12.2±0.9 
10 μM Ketoconazole  4.1±3.0 10.2±4.8 ?  18±6.6 
100 μM Ketoconazole  45.3±6.8 53.3±7.8 11.3±0.0  55.3±23.8 
10 mM Pyrazol  ? 33.1±0.0 ?  19.9±8.0 
100 μM Quercetin  18.0±0.1 2.6±2.0 64.9±0.6  49.3±16.8 
Each data point represents the average and standard deviation of triple determinations, The 
data are expressed as percent inhibition relative to the production activity of MPOL and MP 
NOII in the tissue subcellular fractions as control in the absence of inhibitor. ?:no 
inhibition, NT; not tested. LMs, liver microsomal fraction; LMit, liver mitochondrial 
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????Ms???Mit????????????? IC50????? 0.62??? 0.10 
μM ?????Fig. 12A ??? 12B???????????11β-HSD1 ??????



























Fig. 12. Inhibitory effect of GA on MP reduction activity in liver microsomal (A) 
microsomal and (B) mitochondrial fractions.  
Each data point represents the average of triple determinations and error bars represent the 
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? 4?? 2?????????Wistar????? Ms??? Mit ???? MP?
??????????????????????????????? 2.96??? 0.83 
nmol/min/mg protein????Ms???Mit????????????? GA????
????????????????Fig. 13A??? 13B?? 
???????????????????? GA ????????????IC50
????? 0.13??? 0.07 μM?????Fig. 13A??? 13B??????????
?????? GA??????????????? 0.1 μM?10-7 M????????
?????????????????????1 μM T0504?Ms???Mit????
??????????????????????? 90%??????????data not 





































Fig. 13. Inhibitory effect of GA on MP reduction activity in testis (A) microsomal and 
(B) mitochondrial fractions. 
Each data point represents the average of triple determinations and error bars represent the 
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??????MP ??? GA?????????? MP ?????????????
????? GA????????????Wistar?????MP????? GA??
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GA?????????????? MP? Cmax? MP?????????MP??
0.25???????GA?MP?????????????????????Fig. 14A
??? Table 4?????????MP??? t1/2? GA?????MP??????
??? 2????????? 2?????????????????Fig. 14A???
Table 4?????MP? AUC6h?295.19 ng∙h/mL??MP?????130.81 ng∙h/mL?
????? 2.2???????Table 4????????MPOL??? GA?????
??????MP????????????????Fig. 14B?????????MPOL
???????????tmax? MP ????? 2???? 4???????????
???????? MP ???????????????Fig. 14B?????????
??GA ???? MPOL ? Cmax??? AUC6h????? 54.4 ng/mL ??? 211.65 

























Fig. 14. Plasma concentration profiles of (A) MP and (B) MPOL after the 
co-administration of MP and GA or vehicle to male rats. 
MP was orally administered at a single dose of 50 mg/kg. GA was intraperitoneally 
administered three times at a dose of 10 mg/kg before the MP dose. Each data point represents 
the mean of three separate determinations and error bars represent the standard deviation. 
Asterisk (*) indicates significant differences compared to MP dose group at p < 0.05. ?, MP 
alone; ?, MP plus GA. 
 
 
Table 4 Pharmacokinetic parameters of MP and MPOL after the co-administration of 
MP and GA or vehicle to male rats 
Measured substance  MP MPOL 
Dose  MP alone GA combination MP alone GA combination 
tmax (h)  0.25 0.25 2.00 4.00 
Cmax (ng/mL)  75.50 73.80 114.30 54.4 
t1/2 (h)  1.29 2.26 3.15 ? 
AUC6h (ng∙h/mL)  130.81 295.19 431.15 211.65 
AUC∞ (ng∙h/mL)  137.53 363.03 646.55 ? 
MP was orally administered at a single dose of 50 mg/kg. GA was intraperitoneally 
administered three times at a dose of to 10 mg/kg before the MP dose. The pharmacokinetic 






































- 50 - 
 





????????????MP????? GA????MP NOI?MPOL NOII???
MP NOII??????????????????????????????? Fig. 15
??? Table 5???????MPOL NOI???????????????????
??????????????data not shown??PK????????? 
???MPOL NOII????GA?????MPOL??????????????
????? 0.25???????????????Fig. 15A??????MPOL NOII?
??????????????MP????????????? 4????????
????Fig. 15A???????MPOL NOII? Cmax??? AUC6h????? 18.90 ng/mL
???69.83 ng∙h/mL??MP??????????31.30 ng/mL???119.94 ng∙h/mL?
?? 1/2?????Table 5?????GA???????MP NOII???MP????
??????????MP?? 2??? 4???? MP?????????????
???Fig. 15B???????MP NOII? Cmax??? AUC6h????? 38.80 ng/mL?
?? 163.01 ng∙h/mL???MP?????????? 19.40 ng/mL??? 100.74 ng∙h/mL?



























Fig. 15. Plasma concentration profiles of (A) MPOL NOII, (B) MP NOII and (C) MP 
NOI after the co-administration of MP and GA or vehicle to male rats. 
MP was orally administered at a single dose of 50 mg/kg. GA was intraperitoneally 
administered three times at a dose of 10 mg/kg before the MP dose. Each data point represents 
the mean of three separate determinations and error bars represent the standard deviation. 
Asterisk (*) indicates significant differences compared to the MP dose group at p < 0.05. ?, 
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Table 5. Pharmacokinetic parameters of MPOL NOII and MP NOII after the 
co-administration of MP and GA or vehicle to male rats 
Measured 
substance  MPOL NOII  MP NOII 
Dose  MP alone GA combination MP alone GA combination 
tmax (h)  4.00 4.00 2.00 2.00 
Cmax (ng/mL)  31.30 18.90 19.40 38.80 
t1/2 (h)  ? ? 88.25 10.78 
AUC6h (ng∙h/mL)  119.94 69.83 100.74 163.01 
AUC? (ng∙h/mL)  ? ? 2494.41 629.53 
MP was orally administered at a single dose of 50 mg/kg. GA was intraperitoneally 
administered three times at a dose of to 10 mg/kg before the MP dose. The 
pharmacokinetic parameters were calculated from mean plasma concentrations, n=3. 
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??? Cyt?????????????????Table 6?? 
???Ms?Mit??? Cyt????MP??????????? 2.92?1.10???
1.05 nmol/min/mg protein????? 4?? 2?????Wistar??????????
?????? Ms ????????MP ?????????????? Maser ???
??????????????MP ????? Ms ??? Cyt ??????????
????Maser ????????? 30 ???????? 26)?Ms?? 60 ?????
????????????????? Cyt???????????????????
?????MPOL ???????????? MP NOII ?????????????
?????????Ms???Mit????? 0.55??? 0.02 nmol/min/mg protein?
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Table 6. Activity for the reduction and oxidation of MP in liver microsomal, 
mitochondrial and cytosolic fractions in humans 
 Specific activity (nmol/min/mg protein) 
Measured substance MPOL  MP NOII 
LMs 2.92±0.04  0.55±0.02 
LMit 1.10±0.00  0.02±0.00 
LCyt 1.05±0.07  LLOQ 
Each data point represents the average and standard deviation of triple determinations, 





???? Ms?Mit ??? Cyt ???? MPOL ???????????????
Ms????MP NOII????????????????????????????
??Table 7?? 
???Ms???Mit????MPOL?????????????? 1 μM T0504
?11β-HSD1???????????????????????????? 92???
55%????????????????????????????? Cyt??????
??????????? Cyt????????100 μM quercetin??????????
????????????????????? 70%?? 
MP NOII??????????????Ms?????100 μM ketoconazole???
100 μM quercetin????? CYP???????????????????????
?? 75??? 82%?? 
??????MP????????????Cyt?????????????MPOL
???????????????????? CYP ???????????Wistar ?
?????????????????????MPOL??????????MP NOII
????????????????????????11β-HSD1???CYP????
????Wistar????? Ms??? Mit ???? MP?????????????
 





Table 7. Effects of various inhibitors on the production activities of MPOL and MP NOII 
in human liver microsomal, mitochondrial, and cytosolic fractions 
Measured substance  MPOL  MP NOII 
Subcellular fraction LMs LMit LCyt  LMs 
1 μM T0504  92.3±1.4 54.5±1.5 6.3±1.4  ? 
100 μM Phenobarbital  1.2±0.0 ? 9.7±4.1  6.2±0.6 
1 mM Phenobarbital  11.4±0.4 11.3±6.4 6.2±1.5  12.3±0.9 
10 μM Ketoconazole  ? 9.8±0.0 5.5±4.4  34.7±0.3 
100 μM Ketoconazole  ? 16.1±5.2 9.6±0.0  75.2±1.6 
10 mM Pyrazol  ? ? 3.8±4.6  7.7±2.9 
100 μM Quercetin  ? 25.6±7.9 68.6±6.1  82.2±0.9 
Each data point represents the average and standard deviation of triple determinations, The 
data are expressed as percent inhibition relative to the production activity of MPOL and MP 
NOII in the tissue subcellular fractions as control in the absence of inhibitor. ?:no 









?????? 17, 18, 25, 26)????MP ?????????????????CYP?SD
????? Ms???????????? 69)????????Wistar ???????
? MP ???????????????????????Wistar ?????????
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GA? 11β-HSD1??? 11β-HSD2??????????????????????
?????????????????? NADPH??? NAD+?????? 75-78)??
???????Wistar????????MPOL?????????????????






???????????????????IC50????? 0.62??? 0.10 μM?Fig. 12??
???GA???Ms???Mit?????????????????????IC50?
???? 0.13??? 0.07 μM?Fig. 13???????????MPOL???????
? 11β-HSD1????????????????????????????????










? 11β-HSD1?????????????????? 73, 79)????MP??????
?GA?????MP?????????MP??? 2????????????Cmax
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?????Cmax??? AUC6h?MP??????? 1/2?????Fig. 15A??? Table 
7?????MP NOII??????? GA???????? 2?4?????????
???? Cmax???AUC6h????????? 2??? 1.6?????????Fig. 15B








































? 6?? ?? 
 
?????Wistar????????MP???????????????????





















?????10-7 M????????????????? Ms??? Mit ???? MP




NOII ??? MP ??????????????????????? MP ??? MP 
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?????????????? in vitro??? in vivo??????????????
????????????? 
 




















MP???????? MPOL? MP? AUC???? 4?????????????
??? 11)?????????????????? 4???????MPOL NOII?MP 
NOII?MPOL NOI???MPOL???????????? SD??????????
???????????????????????????????MP?????
???????MPOL NOII???MPOL NOI?MPOL???????????? 
 





























4?MP? in vitro??? in vivo???? 
 
Wistar?????????MPOL??????????Ms?????Mit???



































??? m-chloroperoxybenzoic acid?????????? magnesium sulfate?????
?????????????????????? T0504???????glycyrrhetinic 
acid?GA?? Sigma-Aldrich?phenobarbital ??? quercetin ??????ketoconazole
??? pyrazol????? HPLC????????????? 3-benzoylpridine ???
?????????????????? NADP+?glucose-6-phosphate ???







MP? 5??????????MPOL?MP NOI??? II?????MPOL NOI?




Kraulis? 80)???????????????15 mL??MP?50 mg??????
???? NaBH4?????50 mg?????????? 60?????????????
??????? mL??????????????????15 mL?? 3?????
 








2?MP NOI??? II??? 
Crooks? 81)????????????????50 mL??MP?600 mg??????
m-chloroperoxybenzoic acid?????1.0 g????????????? 10?????
?????????????????/??????8?2 V/V??????????
TLC ???????????? MP NOI ??? II ?????????????? 3
????????????????????????????????????MPOL
???????????????????2×40 cm????MP NOI??? II???
??????????????????????????? 
 
3?MPOL NOI??? II??? 
Kraulis? 80)???????????????15 mL???2??????MP NOI
??? II????? 50 mg?????????? NaBH4?50 mg?????????
? 60 ????????????MPOL ???????????????MPOL NOI
??? II?????????????????????????????? 
 
??? 5 ??????? 1H-NMR ?????????????????????
Damani???? Crooks????????????????? 16, 81)? 
  
 








?????????? Sep-Pak Plus C18 ???????????Waters?USA???
??80%?????/10 mM Na-K???????pH8??????????? 2??
??????????????????????????????????????
???????? 3??? 4?????? 
 
2?HPLC-UV?? 
HPLC-UV?????????????????????? 40 μL? HPLC???
??HPLC??????????? GL????????????????? 
 
HPLC-UV ???GL-7480 ?????????GL-7410?UV ????GL-7450???
??????GL-7432?GL?????? 
??????Inertsil ODS-3?C18?5 μm?4.6 ? 250 mm? 
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????20%??????A???? 50%??????B???????? 
???min? A?%? B?%? C?%? 
Initial 100 0 0 
10 100 0 0 
35 0 100 0 
45 0 100 0 
45.1 0 0 100 
50 0 0 100 







Wistar????? 8???????9?????????? SLC?? 
 
2?MP?????? 

























??1 mL?? 10 mM Na-K???????pH8?1 mL?????????Sep-Pak Plus 
C18 ???????????Waters?USA?? apply???10 mM Na-K?????
??pH8?4 mL???? 10%?????/10 mM Na-K???????pH8?????
??1.5 mL??????80%?????/10 mM Na-K???????pH8?????
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Wistar????? 8???????9?????????? SLC?? 
 
?2?MP?????????????????? 





4?????????? Wistar????? 7????????? SLC??8???
????? 
 















KAC????????????????????????700 ? g?10 min?4?C???
????????????9,000 ? g?20 min?4?C?????????? S9????
S9 ????????????????????????????????????
?9,000 ? g?20 min?4?C???????????Mit????S9????????
?105,000 ? g?60 min?4?C?????????? Cyt????Cyt????????





NADPH?????????1.3 mM NADP??3.3 mM G-6-P?3.3 mM MgCl2?0.4 units/mL 
G-6- PDH????? 100 mM Na/K??? buffer?pH7.4??????????????
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??????????????????????? 1/10?????????????
??????? T0504??????1 μM??phenobarbital??????100??? 1000 
μM??ketoconazole??????10??? 100 μM??pyrazol??????10 mM??
quercetin??????100 μM?????????????????????????
???????????????????????????? 2.5%???????







???????????????? Bicinchoninic acid?BCA??????? 82???
?????????????????????????????????????
??????Mit?Ms??? Cyt?? 20μL???? Bicinchoninic acid/CuSO4?5H2O
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????????? MP ??????????????????????
non-parametric Kruskal-Wallis??? Dunn’s test?????????????Wistar?




Wistar?????????? 270 g??Ms??? 4? 2??? 3???????
??Ms? 0.6%???? X-100??????????????? 20 mg/mL?????
? 1????????????????Ms? 105,000×g? 60??????????
?????????????0.05%???? X-100?0.5 mM EDTA??? 10 mM 2-?
???????????? 0.01 M ???????pH7.4????? A???????
?????????????? 10,000×g? 20?????????????????
???? A? 30 mL/h?????????? DEAE-Sephacel????2.5×18 cm??
???????? A?????0?0.3 M NaCl?????? A?????????900 
mL?????MP????????????? 0.1 M NaCl???????????
????????????? 0.05????? X-100??? 10 mM 2-???????
?????? 0.01 M???????pH 7.4????? B?????????????






0.1 M???????pH 6.0?????????????????????700 μL??
??????????? MP ????????????????? 30?C ? NADPH
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??????????? UV-240???????????MP??????????
? NADPH? 340 nm?????????????????????unit???1??


















???????? 4? 5???????????? 
 
2?GA???? 
GA???? Lin? 73)?????????????MP???????? GA??
???? 2?????????????? GA?10 mg/kg?? 1? 3???????
 
- 76 - 
 




?? 0.25?0.5?1?2?4 ??? 6 ?????????????????????
?????? 3? 3??1??????????????????-80°C?????? 
 
4?????? 
???? 3? 4??1???????????HPLC??????????? 
 
5?????? 









In vivo??? in vitro???????????3???????????????
??In vitro???? MPOL????????????? GA??????????














??????????????????????? ??????? ????? ?
????? ?? ???????????????? 
 
??????????????????????????????? ??????
???? ??????????? ??????????????? 
 
???????????????????????????????????? ?
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